Bimekizumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 457 publications

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System.

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System.

Journal: JAAD international

Published: April 13, 2026

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Journal: Rheumatology and therapy

Published: April 08, 2026

Psychiatric safety of bimekizumab versus interleukin-23 inhibitors in psoriasis: A real-world TriNetX cohort study.

Psychiatric safety of bimekizumab versus interleukin-23 inhibitors in psoriasis: A real-world TriNetX cohort study.

Journal: JAAD international

Published: March 30, 2026

Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.

Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.

Journal: The Journal of dermatological treatment

Published: March 09, 2026

Bimekizumab for recalcitrant pyoderma gangrenosum.

Bimekizumab for recalcitrant pyoderma gangrenosum.

Journal: JAAD case reports

Published: March 09, 2026

Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics.

Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics.

Journal: Journal of drugs in dermatology : JDD

Published: March 04, 2026

Benefits and Costs of Biologics and Phototherapy in Psoriasis Treatment.

Benefits and Costs of Biologics and Phototherapy in Psoriasis Treatment.

Journal: JAMA dermatology

Published: February 25, 2026

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension.

Journal: JAMA dermatology

Published: February 18, 2026

Bimekizumab-induced paradoxical palmoplantar pustular psoriasis.

Bimekizumab-induced paradoxical palmoplantar pustular psoriasis.

Journal: JAAD case reports

Published: February 13, 2026

Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab.

Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab.

Journal: Journal of drugs in dermatology : JDD

Published: February 05, 2026

Biological Treatment of Psoriasis-Data So Far.

Biological Treatment of Psoriasis-Data So Far.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 26, 2026

Response of recalcitrant Blaschkoid psoriasis to bimekizumab: A case report.

Response of recalcitrant Blaschkoid psoriasis to bimekizumab: A case report.

Journal: JAAD case reports

Published: January 19, 2026

Showing 1-12 of 457

Last Updated: 04/28/2026